Unleashing the Potential of Cannabis: Cannabis Bioscience International Holdings Reaches a Historic Valuation

Unleashing the Potential of Cannabis: Cannabis Bioscience International Holdings Reaches a Historic Valuation
HOUSTON, June 17, 2024 (GLOBE NEWSWIRE) -- Cannabis Bioscience International Holdings, Inc. (OTC Pink: CBIH), a company dedicated to medicinal cannabis research for over 15 years, has achieved a 2 billion dollar valuation. This achievement is a testament of the paradigm shift which will allow patients and the medical industry to consider cannabinoids as the first option, not a last resource.
Our significant valuation is the outcome of our unwavering dedication to growth and our persistent commitment to enhancing standards within the healthcare landscape. With a steadfast focus on maintaining market integrity and propelling scientific evolution, our CEO, Dante Picazo, shares his enthusiasm: "Together, we're paving the way for the future of healthcare, and we're enthusiastic about embarking on this shared adventure of advancement."
At CBIH, we embrace a global approach that integrates neuroscience principals, which are revolutionizing modern medicine with clinical, social, and personal implications by understanding the neural-physical relationship, says Dr. Salguero PhD in Science specialized in Microbiology from São Paulo Brazil University.
To conclude, our tireless dedication to excellence compels us to fortify our message daily with groundbreaking and premium solutions for those who depend on us for their well-being. Cannabis Bioscience International Holdings stands optimally positioned to advance its market footprint, innovate fresh therapeutic alternatives, and reassert its unwavering commitment to innovation and excellence in the cannabis industry. Moving ahead, we maintain relentless resolve in our pursuit to redefine norms and positively influence the future landscape of cannabis-based wellness.
FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements. The words "believe," "expect," "should," "intend," "estimate," "projects," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company's current expectations and are subject to a number of risks, uncertainties, and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company's filings, which are on file at www.OTCmarkets.com.
For more information contact us at:
(214) 733-0868
ir@cbih.net
Dante Picazo
CEO - CBIH
Website: www.cbih.net
X: www.twitter.com/cbihstock
Instagram: www.instagram.com/CBIHSTOCK
Investor Relations:
East Coast
Peter Nicosia
Bull in Advantage, LLC
Phone: 585-703-6565
Email: Info@BlueHorseshoeStocks.com
West Coast
Zach Logan
Pacific Capital Markets LLC
Phone: 858.864.0011
Email: pacificcapitalmarketsllc@gmail.com


更多内容,请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
机构
适应症
-
靶点
-
药物
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。